Syremis Therapeutics
1 known investors
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism. Its pipeline includes ST-905, a dual M1/M4 agonist in Phase 1 for schizophrenia, and ST-901, an NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression.